KBC Group
ALXN

KBC Group’s Alexion Pharmaceuticals ALXN Stock Holding History

KBC Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-116,026
Closed -$21.3M – 1348
2021
Q2 		$21.3M Sell
116,026
-40,298
-26% -$6.92M 0.08% 253
2021
Q1 		$23.9M Buy
156,324
+6,851
+5% +$1.06M 0.1% 235
2020
Q4 		$23.4M Buy
149,473
+58,404
+64% +$7.5M 0.11% 207
2020
Q3 		$10.4M Buy
91,069
+25,776
+39% +$2.78M 0.06% 286
2020
Q2 		$7.33M Buy
65,293
+6,082
+10% +$646K 0.05% 324
2020
Q1 		$5.32M Sell
59,211
-539
-0.9% -$52.9K 0.04% 365
2019
Q4 		$6.46M Buy
59,750
+923
+2% +$98.7K 0.04% 408
2019
Q3 		$5.76M Buy
58,827
+1,513
+3% +$171K 0.04% 422
2019
Q2 		$7.51M Hold
57,314
– – 0.06% 361
2019
Q1 		$7.75M Sell
57,314
-4,483
-7% -$557K 0.06% 341
2018
Q4 		$6.02M Sell
61,797
-135,389
-69% -$16M 0.07% 312
2018
Q3 		$27.4M Buy
197,186
+55,794
+39% +$7M 0.21% 127
2018
Q2 		$17.6M Buy
141,392
+113,522
+407% +$13.3M 0.15% 181
2018
Q1 		$3.11M Buy
27,870
+7,316
+36% +$874K 0.03% 481
2017
Q4 		$2.46M Sell
20,554
-6,373
-24% -$776K 0.02% 540
2017
Q3 		$3.78M Sell
26,927
-3,018
-10% -$410K 0.03% 453
2017
Q2 		$3.64M Sell
29,945
-112,361
-79% -$13.1M 0.04% 450
2017
Q1 		$17.3M Buy
142,306
+53,666
+61% +$6.92M 0.16% 160
2016
Q4 		$10.8M Buy
88,640
+68,732
+345% +$8.41M 0.11% 237
2016
Q3 		$2.44M Buy
19,908
+903
+5% +$116K 0.03% 525
2016
Q2 		$2.22M Sell
19,005
-22,758
-54% -$3.23M 0.03% 513
2016
Q1 		$5.81M Buy
41,763
+1,465
+4% +$215K 0.1% 260
2015
Q4 		$7.69M Buy
40,298
+18,160
+82% +$3.17M 0.14% 179
2015
Q3 		$3.46M Buy
22,138
+7,045
+47% +$1.29M 0.07% 317
2015
Q2 		$2.73M Sell
15,093
-17,596
-54% -$3.04M 0.04% 460
2015
Q1 		$5.67M Sell
32,689
-22,515
-41% -$4.08M 0.07% 287
2014
Q4 		$10.2M Buy
55,204
+34,567
+168% +$6.41M 0.12% 202
2014
Q3 		$3.42M Sell
20,637
-71,937
-78% -$11.8M 0.12% 237
2014
Q2 		$14.5M Buy
92,574
+60,924
+192% +$9.62M 0.17% 152
2014
Q1 		$4.82M Sell
31,650
-24,910
-44% -$3.96M 0.08% 306
2013
Q4 		$7.52M Buy
56,560
+10,777
+24% +$1.29M 0.11% 239
2013
Q3 		$5.32M Sell
45,783
-34,315
-43% -$3.76M 0.09% 295
2013
Q2 		$7.39M Buy
+80,098
New +$7.72M 0.14% 190

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

KBC Group's ALXN Position: Q3 2021 in Review

KBC Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 116,026 shares — an estimated $21.3M sold.

KBC Group first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $27.4M in Q3 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • KBC Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • KBC Group sold 116,026 Alexion Pharmaceuticals shares in Q3 2021, an estimated $21.3M.
  • KBC Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • KBC Group's Alexion Pharmaceuticals position peaked at $27.4M in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on KBC Group's 13F filing for Q3 2021, filed 10 Nov 2021.